Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 15 Parkinson's papers of 9,402 | 0.64 |
| pathways Reactome | 22 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5860
Sealed predictions
- SMAD3 in dopamine neurons, braak-0.65 (p 0.058) → -0.02 (p 0.962)receipt 5867
Swarm cases
receipt 5867: SMAD3 in dopamine neurons, braak
- power
- full sample -0.40 (p 0.101, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.140, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.030, n 18). not the mix.
- skeptic
- leave-one-out range -0.52 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.101, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMAD3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts